N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.65p
   
  • Change Today:
    -0.025p
  • 52 Week High: 3.07
  • 52 Week Low: 0.60
  • Currency: UK Pounds
  • Shares Issued: 268.78m
  • Volume: 1,668,891
  • Market Cap: £1.75m

Deal with Barclays    Trade now with Barclays Stockbrokers

N4 Pharma chooses Ardena as contract manufacturing partner

By Josh White

Date: Tuesday 01 Sep 2020

LONDON (ShareCast) - (Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed the API and nanomedicines business unit of Ardena as its contract development and manufacturing organisation partner for the technology transfer and upscaling manufacture of 'Nuvec', it announced on Tuesday.
The AIM-traded firm said the contract was divided into three stages, with the first being establishing an understanding of the current manufacturing process, scale-up and analysis of the transfer of technology.

It said the second phase would see process optimisation and scale-up, resulting in the manufacture and analysis of a non-GMP 50g batch of Nuvec, with the third phase being the manufacture, testing and product certification of Nuvec for 'Good Manufacturing Practice' (GMP) status.

The manufacture would initially be for the fundamental "naked" Nuvec silica nanoparticles, although Ardena has the ability to produce functionalised particles as could be required from time to time, the board said.

N4 described Ardena as a contract development and manufacturing organisation based in the Netherlands, with substance and drug product manufacturing capability.

It said it was experienced in the manufacture of nanoparticles, which was of particular relevance for Nuvec.

Ardena also has a GMP manufacturing, analytical and product release capability.

"We are delighted to be working with Ardena as our tech transfer and manufacturing partner," said chief executive officer Nigel Theobald.

"As we look to continue the advancement of Nuvec and its applications it is increasingly important that we have access to a consistent Nuvec product across our studies together with the potential to move to GMP certification as and when required and Ardena can provide this."

At 1553 BST, shares in N4 Pharma were up 4.3% at 12.12p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.65p
Change Today -0.025p
% Change -3.70 %
52 Week High 3.07
52 Week Low 0.60
Volume 1,668,891
Shares Issued 268.78m
Market Cap £1.75m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:20 1,428 @ 0.70p
16:20 344,883 @ 0.64p
16:14 160,623 @ 0.64p
15:46 1,000 @ 0.60p
15:40 700 @ 0.60p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page